5-(123)I-A-85380 binding to the α4β2-nicotinic receptor in mild cognitive impairment.
Treatments currently licensed for Alzheimer's dementia target cholinergic brain systems. In vivo nicotinic receptor binding may provide an early marker of illness and treatment suitability. In this pilot, we examined nine patients with amnestic mild cognitive impairment (MCI) and 10 age and edu...
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
2010
|